ClinicalTrials.gg
RecruitingNCT06287619POAMUpdated Feb 10, 2026

Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery

A Phase 2 interventional study of Monoferric Injectable Product and 0.9% sodium chloride solution in Chronic Iron Deficiency Anaemia and Cardiac Surgery, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies testing iron isomaltoside 1000 in Iron Deficiencies — 9 open to participants now, 9 under way, 2 of them phase 3. iron isomaltoside 1000 · Iron Deficiencies.

Planned enrollment
19th of 21
60 · median 170
Started
2025
with 3 others
Phase 2
Only one
of the 21
Registered
16th of 21
by date
Lead sponsor
1 of 21
University Health Network, Toronto

Among the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, this one is the 19th largest by planned enrollment, is one of 4 that started in 2025, is the only one in phase 2, and was the 16th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

9 of the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, or all of them as a file.
02

Study summary

POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT investigating whether, in patients with chronic iron-deficiency anemia undergoing cardiac surgery, IV iron therapy in the postoperative period (initiated shortly after surgery, and repeated at 42 days after surgery, if needed) improves clinical outcomes (days alive and out of hospital at 90 days after surgery; DAOH-90) relative to placebo.

03

Conditions studied

  • Chronic Iron Deficiency Anaemia
  • Cardiac Surgery

Browse trials for

Keywords

  • Ferric derisomaltose (Monoferric)
  • Intravenous Iron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who are undergoing any non-emergency open cardiac surgery and who meet all following criteria:

  1. Age greater than 18 years old
  2. Preoperative iron-deficiency with or without anemia (defined as \<130 g/L) with any one of:

    1. ferritin ≤100 μg/l; or
    2. ferritin ≤ 300 μg/L and transferrin saturation ≤ 20%; or
    3. reticulocyte Hb content \< 29 pg, where available

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for the study:

  1. specialized procedures (e.g., ventricular assist device insertion, thoracoabdominal aneurysm, complex adult congenital surgery and heart transplant)
  2. established to IV iron:

    1. to the iron product
    2. history of >2 food and/or drug allergic reactions (excluding drug intolerance)
    3. non-iron deficiency anemias such as myelodysplastic syndrome
    4. history of iron overload or disturbances in use of iron such as hemochromatosis or hemosiderosis
    5. decompensated liver cirrhosis (MELD ≥ 19) or active hepatitis
    6. active infection
  3. preoperative unstable hemodynamics defined as the requirement for vasopressors or inotropes, or active bleeding (as noted in the clinical record and/or defined as a requirement for red blood cell transfusion for ongoing clinical bleeding)
  4. refusal of blood products for religious or other reasons
  5. known pregnancy
  6. already enrolled in this trial
  7. enrolment in another interventional trial which may impact anemia or transfusion management (for example, a trial of hemostatic therapies, such as tranexamic acid)
  8. receipt of intravenous iron at any point in the 6 weeks prior to randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Patients randomized to the IV iron group will receive 1000 mg ferric derisomaltose (Monoferric) diluted in 100 mL of 0.9 % sodium chloride solution, via intravenous infusion over 1 hour using an opaque IV bag and tubing for blinding.

    Drug: Monoferric Injectable Product

  • Placebo comparator
    Control group

    Patients randomized to the placebo group will receive 100 mL of 0.9 % sodium chloride solution via intravenous infusion using an opaque IV bag and tubing for blinding.

    Other: 0.9% sodium chloride solution

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferric derisomaltose will be prepared by an unblinded research pharmacist/delegated staff as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.

    Also known as: Ferric derisomaltose

  • Other0.9% sodium chloride solution

    Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).

06

What researchers measure

Primary outcomes

  1. Feasibility Outcome 1: Percentage of major protocol deviations

    Percentage of major protocol deviations with a feasibility threshold of ≤ 5% (i.e., treatment not according to randomization allocation or dosing schedule; treatment initiated in ineligible patients or outside of allotted periods)

    Time frame: through study completion, an average of 1 year.

  2. Feasibility Outcome 2: Adequate patient enrollment

    Adequate patient enrollment defined as ≥20% of eligible patients enrolled.

    Time frame: through study completion, an average of 1 year.

  3. Feasibility Outcome 3: Percentage of patients lost to follow-up at 90 days

    Percentage of patients lost to follow-up at 90 days with a feasibility threshold of ≤ 5%.

    Time frame: through study completion, an average of 1 year.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Bartoszko J, Miles S, Ansari S, Grewal D, Li M, Callum J, McCluskey SA, Lin Y, Karkouti K. Postoperative intravenous iron to treat iron-deficiency anaemia in patients undergoing cardiac surgery: a protocol for a pilot, multicentre, placebo-controlled randomized trial (the POAM trial). BJA Open. 2024 Jul 27;11:100303. doi: 10.1016/j.bjao.2024.100303. eCollection 2024 Sep. PubMed 39161801 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Apr 3, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06287619
Collaborators
Kingston Health Sciences Centre, Sunnybrook Health Sciences Centre, Heart and Stroke Foundation of Canada
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Apr 3, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Keyvan Karkouti, MD
Contact
Keyvan.Karkouti@uhn.ca
416-340-4800 ext. 8597
Deep Grewal
Contact
Deep.Grewal@uhn.ca
416-340-4800 ext. 4221
Justyna Bartoszko, MD
principal investigator · University Health Network, Toronto
Jeannie Callum, MD
principal investigator · Kingston Health Sciences Centre
Yulia Lin, MD
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion